Capstone Asset Management Co. lowered its stake in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) by 2.6% during the second quarter, Holdings Channel reports. The institutional investor owned 27,590 shares of the specialty pharmaceutical company’s stock after selling 750 shares during the period. Capstone Asset Management Co.’s holdings in SciClone Pharmaceuticals were worth $303,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. LS Investment Advisors LLC increased its position in SciClone Pharmaceuticals by 425.2% in the first quarter. LS Investment Advisors LLC now owns 10,320 shares of the specialty pharmaceutical company’s stock worth $101,000 after buying an additional 8,355 shares during the period. BNP Paribas Arbitrage SA increased its position in SciClone Pharmaceuticals by 14.4% in the first quarter. BNP Paribas Arbitrage SA now owns 10,482 shares of the specialty pharmaceutical company’s stock worth $103,000 after buying an additional 1,320 shares during the period. Municipal Employees Retirement System of Michigan increased its position in SciClone Pharmaceuticals by 2.7% in the first quarter. Municipal Employees Retirement System of Michigan now owns 11,660 shares of the specialty pharmaceutical company’s stock worth $114,000 after buying an additional 310 shares during the period. Mason Street Advisors LLC increased its position in SciClone Pharmaceuticals by 7.9% in the first quarter. Mason Street Advisors LLC now owns 12,037 shares of the specialty pharmaceutical company’s stock worth $118,000 after buying an additional 881 shares during the period. Finally, Airain ltd acquired a new position in SciClone Pharmaceuticals during the first quarter worth $131,000. 73.26% of the stock is owned by institutional investors.

SciClone Pharmaceuticals, Inc. (SCLN) remained flat at $11.05 on Monday. 154,189 shares of the company’s stock were exchanged. The company has a 50-day moving average of $10.97 and a 200-day moving average of $10.15. SciClone Pharmaceuticals, Inc. has a one year low of $8.55 and a one year high of $11.43. The firm has a market capitalization of $576.71 million, a PE ratio of 13.63 and a beta of 1.71.

SciClone Pharmaceuticals (NASDAQ:SCLN) last released its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported $0.26 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.02. The business had revenue of $44.52 million for the quarter. SciClone Pharmaceuticals had a net margin of 27.39% and a return on equity of 20.24%. On average, equities research analysts forecast that SciClone Pharmaceuticals, Inc. will post $0.94 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This report was reported by Watch List News and is owned by of Watch List News. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/capstone-asset-management-co-lowers-stake-in-sciclone-pharmaceuticals-inc-scln/1487559.html.

Separately, Maxim Group reaffirmed a “hold” rating on shares of SciClone Pharmaceuticals in a research report on Thursday, June 8th.

In other SciClone Pharmaceuticals news, CEO Friedhelm Blobel sold 70,000 shares of the company’s stock in a transaction dated Tuesday, June 20th. The shares were sold at an average price of $10.91, for a total transaction of $763,700.00. Following the sale, the chief executive officer now directly owns 152,209 shares of the company’s stock, valued at $1,660,600.19. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Wilson Wai-Shun Cheung sold 40,500 shares of the company’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $10.75, for a total transaction of $435,375.00. Following the sale, the chief financial officer now directly owns 14,372 shares in the company, valued at $154,499. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 235,500 shares of company stock worth $2,479,764. Insiders own 5.16% of the company’s stock.

About SciClone Pharmaceuticals

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Want to see what other hedge funds are holding SCLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN).

Institutional Ownership by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)

Receive News & Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.